drugset
drugset / Trial / NCT05241392

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

NCT05241392 ↗

Phase 1 Active not recruiting 30 enrolled Beijing Tiantan Hospital
NaSequentialOpen-labelTreatment

Summary

This is an open, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability and preliminary effectiveness of B7-H3-targeting Chimeric Antigen Receptor-T (CAR-T) cell therapy on patients with recurrent glioblastomas. The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.

Timeline

Start
2022-01-27
Primary completion
2024-11-30
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject B7-H3-targeting CAR-T cells Cell therapy 2e+07 cells Other
Subject B7-H3-targeting CAR-T cells Cell therapy 6e+07 cells Other
Subject B7-H3-targeting CAR-T cells Cell therapy 1.5e+08 cells Other
Subject B7-H3-targeting CAR-T cells Cell therapy 4.5e+08 cells Other
Subject B7-H3-targeting CAR-T cells Cell therapy 9e+08 cells Other

Indications

glioblastoma